Literature DB >> 12924832

Off-label applications for SSRIs.

Kimberly J Stone1, Anthony J Viera, Christopher L Parman.   

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are widely used because of their safety, tolerability, and demonstrated efficacy across a broad range of clinical conditions. Medical literature supports the use of SSRIs for the treatment of many conditions outside of the indications approved by the U.S. Food and Drug Administration. SSRIs offer a reasonable alternative to traditional therapy for generalized anxiety disorder. A side effect of SSRIs coincidentally provides therapy for premature ejaculation. SSRIs may reduce the frequency and severity of migraine headaches and are possibly effective in reducing the pain of diabetic neuropathy. When taken in combination with tricyclic antidepressants, SSRis offer more potent therapy for fibromyalgia than either agent alone. SSRIs appear to be effective in some patients with neurocardiogenic syncope that is refractory to standard therapies. Clinical experience supported by ongoing research continues to expand on the broad array of therapeutic applications for this class of medication.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12924832

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  20 in total

Review 1.  Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.

Authors:  Rosa Lerose; Pellegrino Musto; Michele Aieta; Carla Papa; Alfredo Tartarone
Journal:  Eur J Clin Pharmacol       Date:  2011-12-14       Impact factor: 2.953

Review 2.  Off-label prescribing in older patients.

Authors:  Stephen H D Jackson; Paul A F Jansen; Arduino A Mangoni
Journal:  Drugs Aging       Date:  2012-06-01       Impact factor: 3.923

3.  Ten common questions (and their answers) about off-label drug use.

Authors:  Christopher M Wittich; Christopher M Burkle; William L Lanier
Journal:  Mayo Clin Proc       Date:  2012-08-06       Impact factor: 7.616

4.  Prescribing gabapentin off label: Perspectives from psychiatry, pain and neurology specialists.

Authors:  Christine Fukada; Jillian Clare Kohler; Heather Boon; Zubin Austin; Murray Krahn
Journal:  Can Pharm J (Ott)       Date:  2012-11

5.  Paternal dapoxetine administration induced deterioration in reproductive performance, fetal outcome, sexual behavior and biochemistry of male rats.

Authors:  R ElMazoudy; N AbdelHameed; A ElMasry
Journal:  Int J Impot Res       Date:  2015-09-24       Impact factor: 2.896

6.  Off-label prescribing patterns of antiemetics in children: a multicenter study in Italy.

Authors:  Davide Zanon; Luca Gallelli; Francesca Rovere; Rossella Paparazzo; Natalia Maximova; Marzia Lazzerini; Antonio Reale; Tiziana Corsetti; Salvatore Renna; Tullia Emanueli; Francesco Mannelli; Francesco Manteghetti; Liviana Da Dalt; Caterina Palleria; Nicola Banchieri; Antonio Urbino; Mario Miglietta; Giovanni Cardoni; Adriana Pompilio; Alberto Arrighini; Clara Lazzari; Gianni Messi
Journal:  Eur J Pediatr       Date:  2012-12-04       Impact factor: 3.183

7.  [Monoaminergic transmitters in the cerebrospinal fluid of patients with acute, chronic, and intermittent pain. Interface between pain and depression?].

Authors:  M Strittmatter; D Ostertag; K H Hoffmann; C Paulus; C Fischer; S Meyer
Journal:  Nervenarzt       Date:  2005-04       Impact factor: 1.214

8.  Sertraline inhibits increases in body fat and carbohydrate dysregulation in adult female cynomolgus monkeys.

Authors:  Marnie G Silverstein-Metzler; Carol A Shively; Thomas B Clarkson; Susan E Appt; J Jeffrey Carr; Stephen B Kritchevsky; Sara R Jones; Thomas C Register
Journal:  Psychoneuroendocrinology       Date:  2016-02-21       Impact factor: 4.905

9.  Temporal trends in antidepressant prescribing to children in UK primary care, 2000-2015.

Authors:  Jane Sarginson; Roger T Webb; S Jill Stocks; Aneez Esmail; Shruti Garg; Darren M Ashcroft
Journal:  J Affect Disord       Date:  2017-01-02       Impact factor: 4.839

10.  Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants, Prolactin and Breast Cancer.

Authors:  Janet E Ashbury; Linda E Lévesque; Patricia A Beck; Kristan J Aronson
Journal:  Front Oncol       Date:  2012-12-05       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.